Skip to main content
Caplight Logo









Hedros Biotechnology

Hedros Biotechnology

Private
North CarolinaHealthcare & Life Scienceshttps://www.hedros.bio/

Last Round

Debt

May 28, 2024

Total Funding Raised

$425,000

Company Overview

Hedros Biotechnology is a biotechnology company that operates a research platform providing bacteriophages to fight bacterial infections, with a focus on disease control in aquaculture.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

bacteriophage therapyphage therapyaquaculture healthantibiotic alternativephage cocktailsshrimp farmingAHPND treatmentAHPNDphage discoveryaquatechAI drug discoveryantimicrobial resistanceanimal healthphage development platformvibriosis treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hedros Biotechnology Comparables

Compare Hedros Biotechnology with similar companies based on industry and business-model similarity.

Hedros Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Phagos
79%
Proteon Pharmaceuticals
78%
NexaBiome
77%

Hedros Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtMay 28, 2024
AcceleratorJul 6, 2023
AcceleratorJun 26, 2023

Hedros Biotechnology Investors

Notable investors and investment history

Hedros Biotechnology investors
InvestorRounds
North Carolina Biotechnology CenterDebt
Hatch BlueAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 28, 2024

    $200K debt round from North Carolina Biotechnology Center

  • Jul 6, 2023

    Accelerator round led by Hatch Blue.

Hedros Biotechnology Filings

Explore SEC and related filing metadata, where available.

Hedros Biotechnology filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Hedros Biotechnology's valuation, stock price, and market status.

Is Hedros Biotechnology a public or private company?

Hedros Biotechnology is a private company.

What is the current stock price of Hedros Biotechnology?

Hedros Biotechnology is a private company with no public stock price. No recent secondary market data is available.

How much is Hedros Biotechnology worth (valuation)?

Valuation information for Hedros Biotechnology is not publicly available.

Can I buy Hedros Biotechnology stock?

Hedros Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Hedros Biotechnology's last funding round?

Hedros Biotechnology's most recent funding round was Debt on May 28, 2024.

Who are the main investors in Hedros Biotechnology?

Key investors in Hedros Biotechnology include Hatch Blue.

Will Hedros Biotechnology IPO soon?

No public IPO plans have been announced for Hedros Biotechnology.

How can I track Hedros Biotechnology secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hedros Biotechnology's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNorth Carolina
Year Founded2023
Last FundingMay 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?